Skip to main content
. 2021 Jan 1;11(4):1690–1702. doi: 10.7150/thno.53691

Figure 2.

Figure 2

Number of vaccine candidates against SARS-CoV-2 in (A) clinical and (B) preclinical development, selected according to vaccine platform technology. Classical (conventional) platforms include the inactivated virus, live attenuated virus, protein subunit, and virus-like particle vaccines. To the next-generation platforms belong viral vectored, RNA, DNA and antigen-presenting cells vaccines.